Published in Neurobiol Aging on October 30, 1997
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 3.76
The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A (2002) 2.74
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol (1999) 1.60
Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation (2012) 1.57
The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. J Neurochem (2008) 1.48
Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J Neurochem (2008) 1.45
Complement in the brain. Mol Immunol (2011) 1.41
Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered? J Neuroinflammation (2014) 1.41
Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. J Neuroinflammation (2011) 1.41
Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation (2008) 1.29
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging (2010) 1.25
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology (2015) 1.21
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci (2009) 1.10
Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis (2012) 1.06
Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis (2010) 1.05
Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol Disord Drug Targets (2013) 1.05
Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation (2009) 1.04
Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflammation (2011) 1.02
Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. Curr Opin Neurobiol (2011) 1.01
Deficiency of complement component 5 ameliorates glaucoma in DBA/2J mice. J Neuroinflammation (2013) 0.99
Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int J Alzheimers Dis (2010) 0.98
Plaque complement activation and cognitive loss in Alzheimer's disease. J Neuroinflammation (2008) 0.97
Prevention of the β-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures. J Neuroinflammation (2011) 0.93
Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol Neurobiol (2007) 0.92
Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. J Neuroinflammation (2006) 0.91
PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer's disease. J Cell Mol Med (2009) 0.90
Serine protease HtrA1 accumulates in corneal transforming growth factor beta induced protein (TGFBIp) amyloid deposits. Mol Vis (2013) 0.85
Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease. Mol Med (1999) 0.85
Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation (2013) 0.83
Antimicrobial peptides and complement in neonatal hypoxia-ischemia induced brain damage. Front Immunol (2015) 0.83
The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms. Exp Brain Res (2014) 0.81
CCAAT-enhancer binding protein-β expression and elevation in Alzheimer's disease and microglial cell cultures. PLoS One (2014) 0.80
Using animal models to determine the significance of complement activation in Alzheimer's disease. J Neuroinflammation (2004) 0.79
White matter injury due to experimental chronic cerebral hypoperfusion is associated with C5 deposition. PLoS One (2013) 0.79
What does complement do in Alzheimer's disease? Old molecules with new insights. Transl Neurodegener (2013) 0.79
Epistasis analysis links immune cascades and cerebral amyloidosis. J Neuroinflammation (2015) 0.79
Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology. J Neuroinflammation (2013) 0.79
Elevated angiopoietin-1 serum levels in patients with Alzheimer's disease. Int J Alzheimers Dis (2012) 0.78
DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease. PLoS One (2015) 0.77
Disifin (sodium tosylchloramide) and Toll-like receptors (TLRs): evolving importance in health and diseases. J Ind Microbiol Biotechnol (2007) 0.77
Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs. J Neuroinflammation (2004) 0.76
Cardiovascular disease could be contained based on currently available data! Dose Response (2006) 0.75
Complement membrane attack complex is related with immune-mediated necrotizing myopathy. Int J Clin Exp Pathol (2014) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 60.62
A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 42.18
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell (1980) 9.86
A mechanism for RNA splicing. Proc Natl Acad Sci U S A (1980) 7.76
The DNA sequence and comparative analysis of human chromosome 20. Nature (2002) 7.40
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Two mRNAs with different 3' ends encode membrane-bound and secreted forms of immunoglobulin mu chain. Cell (1980) 6.32
Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana. Nature (1999) 5.03
The contribution of lead-contaminated house dust and residential soil to children's blood lead levels. A pooled analysis of 12 epidemiologic studies. Environ Res (1998) 4.94
The DNA sequence and analysis of human chromosome 6. Nature (2003) 4.75
Sequence analysis of cloned cDNA encoding part of an immunoglobulin heavy chain. Nucleic Acids Res (1979) 4.74
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med (1998) 4.24
The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med (1991) 3.94
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Does measured behavior reflect STD risk? An analysis of data from a randomized controlled behavioral intervention study. Project RESPECT Study Group. Sex Transm Dis (2000) 3.60
Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol (1989) 3.58
The concept and measurement of continuity in primary care. Am J Public Health (1980) 3.54
Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology (1993) 3.42
Immunoglobulin heavy chain genes: demethylation accompanies class switching. Proc Natl Acad Sci U S A (1981) 3.37
Immune adherence by the fourth component of complement. Science (1969) 3.34
An SNP map of human chromosome 22. Nature (2000) 2.99
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest (1973) 2.94
Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A (1992) 2.84
Radiographic assessment of the knee joint in osteoarthritis. Ann Rheum Dis (1992) 2.75
Purification and radiolabeling of human C1q. J Immunol (1981) 2.75
Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci (1985) 2.72
Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII. J Clin Invest (1973) 2.71
The mechanism of the calcium signal and correlation with histamine release in 2H3 cells. J Biol Chem (1984) 2.58
Clinical trial of indomethacin in Alzheimer's disease. Neurology (1993) 2.58
A common sequence of calcium and pH signals in the mitogenic stimulation of eukaryotic cells. Nature (1985) 2.53
Mouse Cmu heavy chain immunoglobulin gene segment contains three intervening sequences separating domains. Nature (1980) 2.52
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
The DNA sequence and biological annotation of human chromosome 1. Nature (2006) 2.42
The classical complement pathway: activation and regulation of the first complement component. Adv Immunol (1985) 2.38
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
Anti-inflammatory drugs and Alzheimer disease. Lancet (1990) 2.31
Changes in activity of some enzymes involved in glucose utilization and formation in developing rat liver. Biochem J (1968) 2.22
Translation of ferritin light and heavy subunit mRNAs is regulated by intracellular chelatable iron levels in rat hepatoma cells. Proc Natl Acad Sci U S A (1987) 2.20
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
The MHC haplotype project: a resource for HLA-linked association studies. Tissue Antigens (2002) 2.16
Arthritis in Saxon and mediaeval skeletons. Br Med J (Clin Res Ed) (1982) 2.12
Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology (1984) 2.11
Characterization of C1q receptor expression on human phagocytic cells: effects of PDBu and fMLP. J Immunol (1986) 2.09
Brain microglia constitutively express beta-2 integrins. J Neuroimmunol (1990) 2.09
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences. Genome Res (2001) 2.04
Studies of the aetiology of neonatal hepatitis and biliary atresia. Arch Dis Child (1977) 2.04
Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol (2001) 2.01
Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol (1992) 2.01
Doctors accept a challenge: self-assessment exercises in continuing medical education. Br Med J (1979) 2.00
Study of an additional 58 DNA markers in five human populations from four continents. Gene Geogr (1991) 1.98
Complement associated peptidase activity of guinea pig serum. I. Role of complement components. J Immunol (1967) 1.97
Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut (1994) 1.96
Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell (1989) 1.93
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol (1996) 1.90
Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol (2001) 1.89
Microglia in degenerative neurological disease. Glia (1993) 1.89
Exon shuffling and intron insertion in serine protease genes. Nature (1985) 1.87
Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum. J Exp Med (1975) 1.86
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science (1975) 1.85
Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J Exp Med (1998) 1.84
Molecular determinants of drug access to the receptor site for antiarrhythmic drugs in the cardiac Na+ channel. Proc Natl Acad Sci U S A (1995) 1.83
Purification and properties of adenosine 5'-triphospae-D-glucose 6-phosphotransferase from rat liver. Biochem J (1966) 1.82
High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia (2006) 1.81
Identification of the gene (SEDL) causing X-linked spondyloepiphyseal dysplasia tarda. Nat Genet (1999) 1.80
Molecular biology. CACA sequences - the ends and the means? Nature (1983) 1.77
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett (2001) 1.75
Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. J Immunol (1974) 1.74
The semantics of procedures and diseases in SNOMED CT. Methods Inf Med (2006) 1.74
The Journal of Infection Control Nursing. Sterilisation in GP surgeries. Nurs Times (1989) 1.73
Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild. J Virol (1994) 1.70
Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene (1998) 1.70
Studies of an additional kindred with hereditary deficiency of the second component of human complement (C2) and description of a new method for the quantitation of C2. J Immunol (1968) 1.69
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Distribution of clusterin in Alzheimer brain tissue. Brain Res (1992) 1.67
Physicochemical and functional characterization of the C1r subunit of the first complement component. J Immunol (1976) 1.67